Tested BLEX 404 mouth liquid with chemotherapy for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1/2 study tests whether BLEX 404 taken by mouth, added to pemetrexed plus cisplatin chemotherapy, is safe and works better for certain people with newly diagnosed advanced lung cancer. It mainly looks for side effects first, and also checks tumor response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 20 and 70 years old
- You have advanced or metastatic non-small cell lung cancer that can’t be removed, and you plan to start first-line (initial) treatment
- Your lung cancer is non-squamous type and has no EGFR gene mutation
- Your general health is fairly good (ECOG 0–2), and you have enough blood counts, liver, and kidney function for chemotherapy
- You have at least one measurable tumor spot on scans and you plan to receive pemetrexed + cisplatin
- You can follow the study plan and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a new oral drug (BLEX 404) together with docetaxel to see how safe it is and how well it works for people with advanced or metastatic triple-negative breast cancer. If you qualify, you would receive docetaxel by plan and also take BLEX 404 by mouth each day.
This Phase 2 study tests whether adding BLEX 404 to gemcitabine can improve outcomes for people with inoperable or metastatic pancreatic cancer. It may help shrink the cancer or slow its growth by combining two treatments.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.
This trial tests SX-682 plus pembrolizumab (an immunotherapy) to treat metastatic or recurrent non-small cell lung cancer (NSCLC). It aims to see how well the combination works and whether it can shrink or control the cancer in people whose tumors have enough PD-L1.
Hear when a new Nonsquamous Nonsmall Cell Neoplasm of Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.